Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 14.32 is 30% above its 5-year average of 11.03, around the middle of its 5-year range (0.00–31.96).
As of the fiscal period ended Tuesday, June 30, 2026. 8.44% below its 12-month average of 15.64.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 14.32.
CURRENT RATIO
14.32
CURRENT RATIO AVG TTM
15.64
CURRENT RATIO AVG 3Y
9.46
CURRENT RATIO AVG 5Y
11.03
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-8.44%
CURRENT VS 3Y AVG
+51.35%
CURRENT VS 5Y AVG
+29.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
+327.54%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$194.13M
Current Ratio
14.32
TTM Avg
15.64
3Y Avg
9.46
5Y Avg
11.03
Market Cap
$195.29M
Current Ratio
7.90
TTM Avg
9.91
3Y Avg
10.86
5Y Avg
18.34
Market Cap
$184.12M
Current Ratio
1.59
TTM Avg
1.58
3Y Avg
1.42
5Y Avg
1.43
Market Cap
$180.47M
Current Ratio
15.70
TTM Avg
3.42
3Y Avg
4.67
5Y Avg
3.16
Market Cap
$178.29M
Current Ratio
11.22
TTM Avg
14.99
3Y Avg
15.44
5Y Avg
13.43
Market Cap
$178.17M
Current Ratio
12.82
TTM Avg
9.83
3Y Avg
6.43
5Y Avg
5.45
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $194.13M | 14.32 | 15.64 | 9.46 | 11.03 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $195.29M | 7.90 | 9.91 | 10.86 | 18.34 |
| Journey Medical Corporation (DERM)vs › | $184.12M | 1.59 | 1.58 | 1.42 | 1.43 |
| Electra Therapeutics Inc. (ETRA)vs › | $205.34M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | 15.70 | 3.42 | 4.67 | 3.16 |
| Compass Therapeutics, Inc. (CMPX)vs › | $178.29M | 11.22 | 14.99 | 15.44 | 13.43 |
| Precision BioSciences, Inc. (DTIL)vs › | $178.17M | 12.82 | 9.83 | 6.43 | 5.45 |
| Cue Biopharma, Inc. (CUE)vs › | $175.94M | 1.25 | 2.29 | 3.57 | 4.16 |
| Coherus Oncology, Inc. (CHRS)vs › | $174.59M | 1.77 | 1.33 | 1.71 | 2.63 |
| Compugen Ltd. (CGEN)vs › | $219.36M | 5.72 | 5.91 | 5.85 | 7.15 |
Current Ratio
14.32
Quick Ratio
14.32
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 14.32 |
| 2026-03-31 | 15.73 |
| 2025-12-31 | 6.87 |
| 2025-09-30 | 9.33 |
| 2025-06-30 | 31.96 |
| 2025-03-31 | 8.68 |
| 2024-12-31 | 8.43 |
| 2024-09-30 | 9.75 |
| 2024-06-30 | 10.61 |
| 2024-03-31 | 10.91 |
| 2023-12-31 | 7.87 |
| 2023-09-30 | 8.52 |
| 2023-06-30 | 8.80 |
| 2023-03-31 | 10.54 |
| 2022-12-31 | 13.72 |
| 2022-09-30 | 24.21 |
| 2022-06-30 | 28.17 |
| 2022-03-31 | 23.55 |
| 2021-12-31 | 17.70 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
